Target Interacting Protein Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T70176 | Target Info | |||
Target Name | Cyclin-dependent kinase 2 (CDK2) | ||||
Synonyms | Sin3 associated polypeptide; SIN3-associated protein; P33 protein kinase; Cell division protein kinase 2; CDKN2 | ||||
Target Type | Clinical trial Target | ||||
Gene Name | CDK2 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Target Interacting Proteins | Top | ||||
---|---|---|---|---|---|
Acid anhydride hydrolases | [+] 2 Acid anhydride hydrolases | + | |||
Interacting Protein Name | DNA replication licensing factor MCM2 (MCM2) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | BM28; CCNL1; CDCL1; D3S3194; MITOTIN; cdc19 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [1] | |||
2 | Biochemical Activity | [2] | |||
Interacting Protein Name | X-ray repair cross-complementing protein 6 (XRCC6) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CTC75; CTCBF; G22P1; KU70; ML8; TLAA | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [3] | |||
2 | Biochemical Activity | [4] | |||
Acyltransferases | [+] 1 Acyltransferases | + | |||
Interacting Protein Name | Breast cancer type 1 susceptibility protein (BRCA1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | BRCAI; BRCC1; BROVCA1; FANCS; IRIS; PNCA4; PPP1R53; PSCP; RNF53 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [5] | |||
2 | Biochemical Activity | [6] | |||
3 | Reconstituted Complex | [5] | |||
Cell cycle related proteins | [+] 7 Cell cycle related proteins | + | |||
Interacting Target Name | Cyclin A2 (CCNA2) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Cyclin-A2; Cyclin-A; Cyclin A; CCNA | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Affinity Capture-Western | [12] | |||
8 | Affinity Capture-Western | [13] | |||
9 | Affinity Capture-Western | [14] | |||
10 | Affinity Capture-Western | [15] | |||
11 | Affinity Capture-Western | [16] | |||
12 | Affinity Capture-Western | [17] | |||
13 | Affinity Capture-Western | [18] | |||
14 | Affinity Capture-Western | [19] | |||
15 | Biochemical Activity | [20] | |||
16 | Co-crystal Structure | [21] | |||
17 | Co-crystal Structure | [22] | |||
18 | Co-crystal Structure | [23] | |||
19 | Co-crystal Structure | [24] | |||
20 | Co-crystal Structure | [25] | |||
Interacting Target Name | G1/S-specific cyclin-E1 (CCNE1) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | G1/S-specific cyclin E; Cyclin E; CCNE | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Affinity Capture-Western | [26] | |||
8 | Affinity Capture-Western | [27] | |||
9 | Affinity Capture-Western | [15] | |||
10 | Affinity Capture-Western | [28] | |||
11 | Affinity Capture-Western | [29] | |||
12 | Affinity Capture-Western | [30] | |||
13 | Affinity Capture-Western | [31] | |||
14 | Affinity Capture-Western | [32] | |||
15 | Affinity Capture-Western | [33] | |||
16 | Affinity Capture-Western | [18] | |||
17 | Affinity Capture-Western | [34] | |||
18 | Affinity Capture-Western | [35] | |||
19 | Biochemical Activity | [36] | |||
20 | Co-fractionation | [37] | |||
Interacting Protein Name | Cyclin-A1 (CCNA1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CT146 | ||||
Evidence Score (E-score) | 11 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [38] | |||
2 | Affinity Capture-Western | [29] | |||
3 | Affinity Capture-Western | [30] | |||
4 | Affinity Capture-Western | [39] | |||
5 | Biochemical Activity | [40] | |||
6 | Co-crystal Structure | [41] | |||
7 | Co-crystal Structure | [42] | |||
8 | Co-localization | [43] | |||
9 | Co-purification | [44] | |||
10 | Reconstituted Complex | [45] | |||
11 | Yeast two hybrid | [46] | |||
Interacting Target Name | G1/S-specific cyclin-E2 (CCNE2) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | G1/Sspecific cyclinE2 | ||||
Evidence Score (E-score) | 9 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Affinity Capture-Western | [47] | |||
8 | Reconstituted Complex | [48] | |||
9 | Yeast two hybrid | [49] | |||
Interacting Target Name | G1/S-specific cyclin-D1 (CCND1) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | PRAD1 oncogene; PRAD1; Cyclin D1; BCL-1 oncogene; BCL-1; BCL1; B-cell lymphoma 1 protein | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [9] | |||
2 | Affinity Capture-MS | [11] | |||
3 | Affinity Capture-Western | [27] | |||
4 | Reconstituted Complex | [27] | |||
Interacting Protein Name | Cyclin-H (CCNH) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CAK; CycH; p34; p37 | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [8] | |||
3 | Affinity Capture-MS | [9] | |||
4 | Biochemical Activity | [27] | |||
Interacting Target Name | Cyclin D (CCND3) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | G1/S-specific cyclin-D3 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-Western | [50] | |||
Cell division cycle proteins | [+] 3 Cell division cycle proteins | + | |||
Interacting Protein Name | Retinoblastoma-associated protein (RB1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | OSRC; PPP1R130; RB; p105.Rb; pRb; pp110 | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [51] | |||
2 | Biochemical Activity | [52] | |||
3 | Biochemical Activity | [53] | |||
4 | Biochemical Activity | [54] | |||
5 | Biochemical Activity | [27] | |||
6 | Biochemical Activity | [55] | |||
7 | Biochemical Activity | [56] | |||
8 | Biochemical Activity | [57] | |||
9 | Biochemical Activity | [58] | |||
10 | Biochemical Activity | [59] | |||
11 | Biochemical Activity | [60] | |||
12 | Biochemical Activity | [30] | |||
13 | Biochemical Activity | [39] | |||
14 | Biochemical Activity | [42] | |||
15 | Biochemical Activity | [61] | |||
16 | Biochemical Activity | [36] | |||
17 | Biochemical Activity | [62] | |||
18 | Biochemical Activity | [63] | |||
19 | Biochemical Activity | [64] | |||
20 | Biochemical Activity | [65] | |||
Interacting Protein Name | Retinoblastoma-like protein 1 (RBL1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CP107; PRB1; p107 | ||||
Evidence Score (E-score) | 8 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [10] | |||
5 | Affinity Capture-MS | [11] | |||
6 | Biochemical Activity | [66] | |||
7 | Biochemical Activity | [67] | |||
8 | Protein-peptide | [32] | |||
Interacting Protein Name | Retinoblastoma-like protein 2 (RBL2) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | P130; Rb2 | ||||
Evidence Score (E-score) | 7 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [10] | |||
5 | Affinity Capture-MS | [11] | |||
6 | Biochemical Activity | [67] | |||
7 | Protein-peptide | [32] | |||
Cullins | [+] 1 Cullins | + | |||
Interacting Protein Name | Cullin-1 (CUL1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [8] | |||
3 | Affinity Capture-Western | [38] | |||
Ester hydrolases | [+] 4 Ester hydrolases | + | |||
Interacting Protein Name | Cyclin-dependent kinase inhibitor 3 (CDKN3) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CDI1; CIP2; KAP; KAP1 | ||||
Evidence Score (E-score) | 5 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Yeast two hybrid | [68] | |||
5 | Yeast two hybrid | [69] | |||
Interacting Target Name | M-phase inducer phosphatase 2 (MPIP2) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Dual specificity phosphatase Cdc25B; CDC25HU2; Cdc25B phosphatase | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Biochemical Activity | [70] | |||
2 | Yeast two hybrid | [71] | |||
Interacting Target Name | Serine/threonine PP2A-alpha (PPP2CA) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform; RP-C; Replication protein C; PP2A-alpha | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Biochemical Activity | [72] | |||
2 | Co-purification | [72] | |||
Interacting Target Name | M-phase inducer phosphatase 1 (MPIP1) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Dual specificity phosphatase Cdc25A; Cdc25A phosphatase | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [73] | |||
2 | Reconstituted Complex | [74] | |||
Histones | [+] 2 Histones | + | |||
Interacting Protein Name | Histone H1.1 (HIST1H1A) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | H1.1; H1A; H1F1; HIST1 | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [75] | |||
2 | Affinity Capture-Western | [76] | |||
3 | Affinity Capture-Western | [77] | |||
4 | Biochemical Activity | [78] | |||
5 | Biochemical Activity | [53] | |||
6 | Biochemical Activity | [79] | |||
7 | Biochemical Activity | [14] | |||
8 | Biochemical Activity | [27] | |||
9 | Biochemical Activity | [15] | |||
10 | Biochemical Activity | [55] | |||
11 | Biochemical Activity | [44] | |||
12 | Biochemical Activity | [80] | |||
13 | Biochemical Activity | [81] | |||
14 | Biochemical Activity | [56] | |||
15 | Biochemical Activity | [28] | |||
16 | Biochemical Activity | [82] | |||
17 | Biochemical Activity | [83] | |||
18 | Biochemical Activity | [84] | |||
19 | Biochemical Activity | [85] | |||
20 | Biochemical Activity | [76] | |||
Interacting Protein Name | Histone H1.0 (H1F0) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | H10; H1FV | ||||
Evidence Score (E-score) | 10 Experimental Evidences | + | |||
1 | Biochemical Activity | [86] | |||
2 | Biochemical Activity | [87] | |||
3 | Biochemical Activity | [16] | |||
4 | Biochemical Activity | [30] | |||
5 | Biochemical Activity | [88] | |||
6 | Biochemical Activity | [64] | |||
7 | Biochemical Activity | [89] | |||
8 | Biochemical Activity | [90] | |||
9 | Biochemical Activity | [91] | |||
10 | Biochemical Activity | [92] | |||
Kinases | [+] 3 Kinases | + | |||
Interacting Target Name | Cyclin-dependent kinase 7 (CDK7) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | TFIIH basal transcription factor complex kinase subunit; Serine/threonine-protein kinase 1; P39 Mo15; MO15; Cell division protein kinase 7; CDKN7; CDK-activating kinase 1; CDK-activating kinase; CAK1; CAK; 39 kDa protein kinase | ||||
Evidence Score (E-score) | 5 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [11] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-Western | [93] | |||
4 | Biochemical Activity | [94] | |||
5 | Biochemical Activity | [27] | |||
Interacting Target Name | CDC7-related kinase (CDC7) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | huCdc7; HsCdc7; Cell division cycle 7-related protein kinase; Cell division cycle 7related protein kinase; CDC7related kinase; CDC7L1 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [95] | |||
2 | Biochemical Activity | [95] | |||
3 | Biochemical Activity | [96] | |||
Interacting Target Name | Cyclin-dependent kinase 6 (CDK6) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Serine/threonine-protein kinase PLSTIRE; Serine/threonine protein kinase PLSTIRE; Cell division protein kinase 6; CDKN6 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Co-localization | [43] | |||
2 | Co-purification | [72] | |||
Lyases | [+] 1 Lyases | + | |||
Interacting Protein Name | Fructose-bisphosphate aldolase A (ALDOA) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | ALDA; GSD12; HEL.S.87p | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [1] | |||
2 | Co-fractionation | [97] | |||
Membrane-bounded channels | [+] 1 Membrane-bounded channels | + | |||
Interacting Target Name | G2/mitotic-specific cyclin B1 (CCNB1) | Patented-recorded Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | G2/mitotic-specific cyclin-B1; Cyclin B1; CCNB | ||||
Evidence Score (E-score) | 8 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Reconstituted Complex | [98] | |||
8 | Reconstituted Complex | [45] | |||
Peptidases | [+] 1 Peptidases | + | |||
Interacting Target Name | JUN activation domain binding protein (COPS5) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Signalosome subunit 5; SGN5; Jun activation domain-binding protein 1; JAB1; CSN5; COP9 signalosome complex subunit 5 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [99] | |||
2 | Affinity Capture-Western | [100] | |||
Pore-forming toxins | [+] 1 Pore-forming toxins | + | |||
Interacting Target Name | Cellular tumor antigen p53 (TP53) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tumor suppressor p53; Phosphoprotein p53; P53; Antigen NY-CO-13 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Biochemical Activity | [101] | |||
2 | Biochemical Activity | [102] | |||
3 | Co-localization | [43] | |||
Transcription regulators | [+] 4 Transcription regulators | + | |||
Interacting Target Name | E2F transcription factor 1 (E2F1) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Transcription factor E2F1; Retinoblastoma-binding protein 3; Retinoblastoma-associated protein 1; RBBP-3; RBBP3; RBAP-1; pRB-binding protein E2F-1; PBR3; E2F-1 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [63] | |||
2 | Biochemical Activity | [103] | |||
3 | Biochemical Activity | [63] | |||
Interacting Protein Name | Transcription factor Dp-1 (TFDP1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | DP1; DRTF1; Dp.1 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [3] | |||
2 | Affinity Capture-Western | [63] | |||
3 | Biochemical Activity | [63] | |||
Interacting Target Name | Forkhead box protein M1 (FOXM1) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Winged-helix factor from INS-1 cells; Winged helix factor from INS-1 cells; WIN; Transcription factor Trident; MPP2; MPM-2 reactive phosphoprotein 2; M-phase phosphoprotein 2; HNF-3/fork-head homolog-11; HNF-3/fork-head homolog 11; HFH-11; HFH11; Hepatocyte nuclear factor 3 forkhead homolog 11; Foxm1b; Foxm1; Forkhead-related protein FKHL16; Forkhead Box (Fox) m1b; FKHL16 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [104] | |||
2 | Biochemical Activity | [105] | |||
Interacting Target Name | Mothers against decapentaplegic homolog 3 (SMAD3) | Preclinical Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | TGF-beta response effector Smad3; Smad3; SMAD family member 3; SMAD 3; Mothers against DPP homolog 3; MMad3; MADH3; Mad3; MAD homolog 3; JV15-2; HSMAD3; HMAD-3 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Biochemical Activity | [52] | |||
2 | Co-localization | [43] | |||
Other proteins | [+] 8 Other proteins | + | |||
Interacting Target Name | Melanoma differentiation-associated protein 6 (CDKN1A) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | WAF1; SDI1; PIC1; P21(WAF1); P21; Melanoma differentiation associated protein 6; MDA-6; MDA6; Cyclin-dependent kinase inhibitor 1; CIP1; CDK-interacting protein 1; CAP20 | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [8] | |||
3 | Affinity Capture-MS | [9] | |||
4 | Affinity Capture-MS | [10] | |||
5 | Affinity Capture-MS | [11] | |||
6 | Affinity Capture-Western | [84] | |||
7 | Affinity Capture-Western | [106] | |||
8 | Affinity Capture-Western | [14] | |||
9 | Affinity Capture-Western | [30] | |||
10 | Affinity Capture-Western | [83] | |||
11 | Affinity Capture-Western | [107] | |||
12 | Affinity Capture-Western | [17] | |||
13 | Affinity Capture-Western | [18] | |||
14 | Affinity Capture-Western | [34] | |||
15 | Affinity Capture-Western | [108] | |||
16 | Affinity Capture-Western | [109] | |||
17 | Affinity Capture-Western | [110] | |||
18 | Affinity Capture-Western | [88] | |||
19 | Affinity Capture-Western | [111] | |||
20 | Affinity Capture-Western | [112] | |||
Interacting Target Name | CDK inhibitor 1B p27Kip1 (CDKN1B) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | p27Kip1; KIP1; Cyclin-dependent kinase inhibitor p27; Cyclindependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Affinity Capture-Western | [26] | |||
8 | Affinity Capture-Western | [106] | |||
9 | Affinity Capture-Western | [14] | |||
10 | Affinity Capture-Western | [15] | |||
11 | Affinity Capture-Western | [113] | |||
12 | Affinity Capture-Western | [30] | |||
13 | Affinity Capture-Western | [83] | |||
14 | Affinity Capture-Western | [107] | |||
15 | Affinity Capture-Western | [114] | |||
16 | Affinity Capture-Western | [17] | |||
17 | Affinity Capture-Western | [18] | |||
18 | Affinity Capture-Western | [108] | |||
19 | Affinity Capture-Western | [110] | |||
20 | Affinity Capture-Western | [115] | |||
Interacting Target Name | S-phase kinase-associated protein 2 (SKP2) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Skp2; P45skp2; FBXL1; F-box/LRR-repeat protein 1; F-box protein Skp2; Cyclin-A/CDK2-associated protein p45; Cyclin A/CDK2-associated protein p45; Cyclin A/CDK2-associated p45 | ||||
Evidence Score (E-score) | 11 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [7] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [8] | |||
4 | Affinity Capture-MS | [9] | |||
5 | Affinity Capture-MS | [10] | |||
6 | Affinity Capture-MS | [11] | |||
7 | Affinity Capture-Western | [116] | |||
8 | Affinity Capture-Western | [38] | |||
9 | Affinity Capture-Western | [109] | |||
10 | Co-crystal Structure | [117] | |||
11 | Reconstituted Complex | [116] | |||
Interacting Protein Name | Cyclin-dependent kinases regulatory subunit 1 (CKS1B) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | CKS1; PNAS.16; PNAS.18; ckshs1 | ||||
Evidence Score (E-score) | 8 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [8] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [9] | |||
4 | Affinity Capture-MS | [10] | |||
5 | Affinity Capture-MS | [11] | |||
6 | Co-crystal Structure | [118] | |||
7 | Co-crystal Structure | [117] | |||
8 | Co-fractionation | [97] | |||
Interacting Protein Name | S-phase kinase-associated protein 1 (SKP1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | EMC19; OCP.II; OCP2; SKP1A; TCEB1L; p19A | ||||
Evidence Score (E-score) | 6 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [9] | |||
2 | Affinity Capture-MS | [3] | |||
3 | Affinity Capture-MS | [10] | |||
4 | Affinity Capture-Western | [38] | |||
5 | Co-crystal Structure | [117] | |||
6 | Reconstituted Complex | [116] | |||
Interacting Target Name | Proliferating cell nuclear antigen (PCNA) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Cyclin | ||||
Evidence Score (E-score) | 5 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [1] | |||
2 | Affinity Capture-MS | [9] | |||
3 | Affinity Capture-Western | [119] | |||
4 | Affinity Capture-Western | [120] | |||
5 | Biochemical Activity | [62] | |||
Interacting Protein Name | DNA replication factor Cdt1 (CDT1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | DUP; RIS2 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [11] | |||
2 | Biochemical Activity | [121] | |||
Interacting Protein Name | Origin recognition complex subunit 2 (ORC2) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | ORC2L | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Biochemical Activity | [122] | |||
2 | Reconstituted Complex | [48] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells. 2011 Apr;29(4):651-9. | ||||
REF 2 | Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem. 2006 Apr 14;281(15):10281-90. | ||||
REF 3 | Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy. Sci Signal. 2015 Apr 7;8(371):rs3. | ||||
REF 4 | Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J Biol Chem. 2004 Aug 6;279(32):33727-41. | ||||
REF 5 | BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol. 1999 Jul;19(7):4843-54. | ||||
REF 6 | BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996 Jul 15;56(14):3168-72. | ||||
REF 7 | Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509. | ||||
REF 8 | The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell. 2015 Jul 16;162(2):425-440. | ||||
REF 9 | A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015 Oct 22;163(3):712-23. | ||||
REF 10 | The protein interaction landscape of the human CMGC kinase group. Cell Rep. 2013 Apr 25;3(4):1306-20. | ||||
REF 11 | Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods. 2013 Apr;10(4):307-14. | ||||
REF 12 | The transcriptional co-activator PCAF regulates cdk2 activity. Nucleic Acids Res. 2009 Nov;37(21):7072-84. | ||||
REF 13 | APOLLON protein promotes early mitotic CYCLIN A degradation independent of the spindle assembly checkpoint. J Biol Chem. 2014 Feb 7;289(6):3457-67. | ||||
REF 14 | Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene. 1997 Sep 25;15(13):1555-63. | ||||
REF 15 | p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett. 2009 Dec 28;286(2):240-9. | ||||
REF 16 | Autocatalytic phosphorylation of CDK2 at the activating Thr160. Cell Cycle. 2007 Apr 1;6(7):843-52. | ||||
REF 17 | cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA. Mol Biol Cell. 2005 Mar;16(3):1527-42. | ||||
REF 18 | ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cyc... J Biol Chem. 2005 Feb 4;280(5):3185-96. | ||||
REF 19 | Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev. 2011 Apr 15;25(8):845-62. | ||||
REF 20 | Characterization of the in vitro reconstituted cyclin A or B1-dependent cdk2 and cdc2 kinase activities. J Biol Chem. 1993 Sep 25;268(27):20443-51. | ||||
REF 21 | 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem. 2004 Jun 17;47(13):3367-80. | ||||
REF 22 | Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3079-82. | ||||
REF 23 | Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure. 2001 May 9;9(5):389-97. | ||||
REF 24 | Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism. Biochemistry. 2002 Jun 11;41(23):7301-11. | ||||
REF 25 | 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):1084-90. | ||||
REF 26 | p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007 Jan 26;128(2):281-94. | ||||
REF 27 | Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H. Eur J Biochem. 1996 Apr 15;237(2):460-7. | ||||
REF 28 | Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J Cell Biochem. 1996 Mar 1;60(3):363-78. | ||||
REF 29 | Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem. 2004 Mar 26;279(13):12695-705. | ||||
REF 30 | CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes. Eur J Cell Biol. 2003 May;82(5):253-61. | ||||
REF 31 | HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression. Mol Cancer. 2010 Nov 23;9:302. | ||||
REF 32 | Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev. 1998 Feb 15;12(4):456-61. | ||||
REF 33 | CDK2 phosphorylation regulates the protein stability of KLF10 by interfering with binding of the E3 ligase SIAH1. Biochim Biophys Acta. 2015 May;1853(5):1174-81. | ||||
REF 34 | p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther. 2010 Jul;9(7):2102-13. | ||||
REF 35 | Centrosome-targeting region of CG-NAP causes centrosome amplification by recruiting cyclin E-cdk2 complex. Genes Cells. 2005 Jan;10(1):75-86. | ||||
REF 36 | Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol. 2001 Jul;3(7):667-74. | ||||
REF 37 | Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo). 2000 Oct;53(10):1191-200. | ||||
REF 38 | Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7451-6. | ||||
REF 39 | Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis. J Biol Chem. 2004 Feb 27;279(9):7438-46. | ||||
REF 40 | Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J Biol Chem. 2000 Feb 4;275(5):3158-67. | ||||
REF 41 | Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther. 2002 Feb-Mar;93(2-3):113-24. | ||||
REF 42 | Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem. 2002 Aug 29;45(18):3905-27. | ||||
REF 43 | Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. J Proteome Res. 2014 Dec 5;13(12):5339-46. | ||||
REF 44 | Reconstitution of cyclin-dependent cdc2 and cdk2 kinase activities in vitro. J Biol Chem. 1993 Sep 25;268(27):20433-42. | ||||
REF 45 | Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol. 1995 Jan;15(1):345-50. | ||||
REF 46 | Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 1997 Mar 1;57(5):913-20. | ||||
REF 47 | Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999 Jan;19(1):612-22. | ||||
REF 48 | Self-assembling protein microarrays. Science. 2004 Jul 2;305(5680):86-90. | ||||
REF 49 | Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. Oncogene. 1998 Nov 26;17(21):2787-98. | ||||
REF 50 | Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol. 2006 Jul;26(13):5070-85. | ||||
REF 51 | Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem. 2006 Feb 10;281(6):3711-21. | ||||
REF 52 | Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004 Jul 8;430(6996):226-31. | ||||
REF 53 | The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity. Oncogene. 1997 Jan 30;14(4):491-8. | ||||
REF 54 | Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol. 1996 Sep;16(9):4673-82. | ||||
REF 55 | PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell. 1998 Dec;2(6):877-85. | ||||
REF 56 | Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007 Jan 26;128(2):269-80. | ||||
REF 57 | Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997 Feb;8(2):287-301. | ||||
REF 58 | Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem. 2003 Jul 25;278(30):27421-31. | ||||
REF 59 | Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997 May 9;272(19):12738-46. | ||||
REF 60 | Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein. Biochem Biophys Res Commun. 1999 Sep 16;263(1):35-40. | ||||
REF 61 | 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. J Med Chem. 2005 Apr 21;48(8):2944-56. | ||||
REF 62 | CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell. 2002 Sep;3(3):339-50. | ||||
REF 63 | Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol. 1997 Jul;17(7):3867-75. | ||||
REF 64 | Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol. 2003 Oct;77(19):10566-74. | ||||
REF 65 | p300 is required for orderly G1/S transition in human cancer cells. Oncogene. 2007 Jan 4;26(1):21-9. | ||||
REF 66 | Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol Cell Biol. 2002 Apr;22(7):2242-54. | ||||
REF 67 | Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol. 1999 Feb;19(2):1460-9. | ||||
REF 68 | KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1731-5. | ||||
REF 69 | The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805-16. | ||||
REF 70 | Biochemical characterization of Cdk2-Speedy/Ringo A2. BMC Biochem. 2005 Sep 28;6:19. | ||||
REF 71 | 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7892-6. | ||||
REF 72 | Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2C alpha and beta 2 isoforms. J Biol Chem. 2000 Nov 3;275(44):34744-9. | ||||
REF 73 | Defining the Protein-Protein Interaction Network of the Human Protein Tyrosine Phosphatase Family. Mol Cell Proteomics. 2016 Sep;15(9):3030-44. | ||||
REF 74 | Roles of active site residues and the NH2-terminal domain in the catalysis and substrate binding of human Cdc25. J Biol Chem. 1996 Mar 1;271(9):5118-24. | ||||
REF 75 | Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7211-6. | ||||
REF 76 | Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 1998 Nov 19;17(20):2637-43. | ||||
REF 77 | Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun. 1999 Apr 13;257(2):609-14. | ||||
REF 78 | Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 1996 Apr 11;380(6574):548-50. | ||||
REF 79 | Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011 Jan 21;144(2):187-99. | ||||
REF 80 | Inhibition of cyclin E-cyclin-dependent kinase 2 complex formation and activity is associated with cell cycle arrest and withdrawal in oligodendrocyte progenitor cells. J Neurosci. 2001 Feb 15;21(4):1274-82. | ||||
REF 81 | Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res. 2005 Jan 15;65(2):587-95. | ||||
REF 82 | Human TopBP1 participates in cyclin E/CDK2 activation and preinitiation complex assembly during G1/S transition. J Biol Chem. 2007 May 18;282(20):14882-90. | ||||
REF 83 | Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene. 1998 May;16(20):2575-83. | ||||
REF 84 | UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell. 2003 Sep 5;114(5):599-610. | ||||
REF 85 | Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation. Biochemistry. 1999 Jul 6;38(27):8713-22. | ||||
REF 86 | Adenosine deaminase acting on RNA 1 accelerates cell cycle through increased translation and activity of cyclin-dependent kinase 2. Shock. 2007 Feb;27(2):214-9. | ||||
REF 87 | The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells. 2004 May;9(5):383-97. | ||||
REF 88 | Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003 Sep;125(3):891-905. | ||||
REF 89 | Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res. 2002 Nov;60(5):257-70. | ||||
REF 90 | Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther. 2006 Sep;5(9):2172-81. | ||||
REF 91 | Identification and characterization of CAC1 as a novel CDK2-associated cullin. Cell Cycle. 2009 Nov 1;8(21):3552-61. | ||||
REF 92 | Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity. J Cell Biochem. 2006 May 1;98(1):128-38. | ||||
REF 93 | Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol. 2006 Jan;13(1):55-62. | ||||
REF 94 | Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol. 2001 Jan;21(1):88-99. | ||||
REF 95 | The replicon initiation burst released by reoxygenation of hypoxic T24 cells is accompanied by changes of MCM2 and Cdc7. J Biochem Mol Biol. 2007 Sep 30;40(5):805-13. | ||||
REF 96 | Human Cdc7-related kinase complex. In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a criticial threonine residue of Cdc7 bY Cdks. J Biol Chem. 2000 Sep 15;275(37):29042-52. | ||||
REF 97 | Panorama of ancient metazoan macromolecular complexes. Nature. 2015 Sep 17;525(7569):339-44. | ||||
REF 98 | A nonproteolytic function of the proteasome is required for the dissociation of Cdc2 and cyclin B at the end of M phase. Genes Dev. 2000 Sep 15;14(18):2344-57. | ||||
REF 99 | Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell. 2010 Dec 10;143(6):951-65. | ||||
REF 100 | CSN5/JAB1 interacts with the centromeric components CENP-T and CENP-W and regulates their proteasome-mediated degradation. J Biol Chem. 2013 Sep 20;288(38):27208-19. | ||||
REF 101 | The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol. 2000 Jul 14;300(3):503-18. | ||||
REF 102 | Regulated expression of cofilin and the consequent regulation of p27(kip1) are essential for G(1) phase progression. Cell Cycle. 2009 Aug;8(15):2365-74. | ||||
REF 103 | Phosphorylation- and Skp1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases. Cancer Res. 2001 Feb 15;61(4):1347-53. | ||||
REF 104 | Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 2004 Apr;24(7):2649-61. | ||||
REF 105 | Regulation of the transcription factor FOXM1c by Cyclin E/CDK2. FEBS Lett. 2006 Mar 20;580(7):1716-22. | ||||
REF 106 | Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell. 1998 Mar;1(4):553-63. | ||||
REF 107 | The CDK inhibitor, p27Kip1, is required for IL-4 regulation of astrocyte proliferation. J Immunol. 1997 Jul 15;159(2):812-9. | ||||
REF 108 | Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol. 2002 Dec;22(23):8184-98. | ||||
REF 109 | Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol Cell Biol. 1999 Jan;19(1):635-45. | ||||
REF 110 | Progesterone inhibits human endothelial cell proliferation through a p53-dependent pathway. Cell Mol Life Sci. 2008 Nov;65(23):3839-50. | ||||
REF 111 | Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells. Oncogene. 2000 Jul 13;19(30):3384-94. | ||||
REF 112 | Induction of p53-independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells. Biochem Cell Biol. 2000;78(2):127-35. | ||||
REF 113 | Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996 Dec 2;15(23):6595-604. | ||||
REF 114 | S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines. J Cell Physiol. 2008 Nov;217(2):558-68. | ||||
REF 115 | Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998 Jul;12(7):941-53. | ||||
REF 116 | p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell. 1995 Sep 22;82(6):915-25. | ||||
REF 117 | Activation of ubiquitin ligase SCF(Skp2) by Cks1: insights from hydrogen exchange mass spectrometry. J Mol Biol. 2006 Oct 27;363(3):673-86. | ||||
REF 118 | Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell. 1996 Mar 22;84(6):863-74. | ||||
REF 119 | A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem. 2000 Jul 28;275(30):22882-7. | ||||
REF 120 | Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell. 1993 Sep;4(9):897-906. | ||||
REF 121 | Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. J Biol Chem. 2005 Jun 17;280(24):23416-23. | ||||
REF 122 | Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol Cell. 2002 Mar;9(3):481-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.